Hyundai Bioscience Co. Ltd (048410 KQ) stock market data APIs
₩9925.6811
132.9(1.3%)
as of July 8, 2025
Try our APIs with
free plan!
Hyundai Bioscience Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
Prev. Close
9925.6811
Open
10058.5822
High
11137.4014
Low
9876.6764
52 wk Range
8650-21388.4516
Market Cap
480 194 M
Shares Outstanding
48 019 K
Revenue
10 709 M
EPS
-139.7684
Beta
1.05
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hyundai Bioscience Co. Ltd data using free add-ons & libraries
Get Hyundai Bioscience Co. Ltd Fundamental Data
Hyundai Bioscience Co. Ltd Fundamental data includes:
- Net Revenue: 10 709 M
- EBITDA: -3 936 676 864
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hyundai Bioscience Co. Ltd News
New
Hyundai Bioscience announces that "Xafty is the only antiviral that can be immediately used for the treatment of Dengue fever"
Hyundai Bioscience presented data at IDWeek™ 2023 that Dengue fever, which has no cure despite the rapid increase in deaths, can be treated with Xafty Hyundai Bioscience offered also to provide Xa...
The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2...
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
- Hyundai Bioscience announcing the receipt of the phase 2 clinical study report of XaftyTM and its plans for the emergency use authorization - Planning fast track process in oversea countries to e...
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
Polytaxel, a novel pain-free anticancer drug, may not require break periods A new standard of care, more convenient than docetaxel, is suggested Hyundai Bioscience to enter clinical trial on pancreati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
